Educational guide
All Product Coas Adamax Peptide 10mg AHK-CU 5 Amino 1mq AOD-9604 ARA-290 Bacteriostatic Reconstitution Water (BAC) BPC-157 Tablets BPC-157 10mg Cagrilintide Cartalax CJC 1295 (no dac) CJC-1295 + Ipamorelin (5mg/5mg) DSIP Epithalon (Epitalon) FOXO4-DRI GHK-Cu C
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Connected reading
Source-derived material selected through this article’s indexed topics.
You'll miss the inflammatory resolution window where BPC-157 provides its clearest benefit—reducing TNF-alpha and IL-6 by 40–50% in the first 2 weeks—but the proliferative and remodeling phases (where TB-500 and GHK-Cu operate) extend for months, so delayed initiation still targets meaningful biological processes. Start with TB-500 and GHK-Cu only if you're past day 21; BPC-157's primary value diminishes after the acute inflammatory phase resolves.
Source: realpeptides.co ↗Skip the missed dose and resume the protocol the following night. Do not double-dose. DSIP doesn't accumulate, so missing one night doesn't disrupt the overall protocol timeline. Some research designs include built-in 'washout' nights to assess baseline sleep architecture between dosing periods. If your protocol is daily for 14 days and you miss day 6, continue through day 15 to maintain 14 total doses.
Source: realpeptides.co ↗If you froze it once at −80°C without prior thawing, it may be salvageable. Thaw it slowly in the refrigerator (not at room temperature) and inspect for particles or cloudiness. If this is the second or third freeze-thaw cycle, discard it. Ice crystal formation during freezing disrupts peptide secondary structure; repeated cycles compound the damage. We've tested frozen peptides after single freeze-thaw events and observed 20–35% activity loss compared to never-frozen controls. Acceptable for some applications, unacceptable for dose-sensitive work.
Source: realpeptides.co ↗Define treatment resistance explicitly: failure to respond to at least two SSRI trials at therapeutic doses for ≥8 weeks each, or benzodiazepine intolerance due to sedation or dependency concerns. Use intranasal Selank at 400 mcg three times daily for 28 days and measure cortisol reactivity through Trier Social Stress Test (TSST) at baseline and endpoint. Treatment-resistant anxiety often correlates with HPA axis dysregulation that SSRIs don't correct. Selank's cortisol-modulating mechanism addresses this gap directly. Include inflammatory biomarkers (IL-6, TNF-alpha) as secondary endpoints, as chronic anxiety elevates systemic inflammation and Selank has demonstrated anti-inflammatory effects in multiple models.
Source: realpeptides.co ↗Discard the vial immediately and do not use it in your protocol. Cloudiness indicates peptide aggregation. IGF-1 LR3 chains have clumped into high-molecular-weight complexes through hydrophobic interactions or improper disulfide bonding, rendering them unable to pass through cell membranes or bind surface receptors. Aggregates are biologically inert and will produce zero anabolic response regardless of dose administered. Aggregation occurs from temperature excursions above 25°C during storage, repeated freeze-thaw cycles, or mechanical shearing during reconstitution. Prevent it by storing lyophilized peptide at −20°C, shipping with cold packs, and reconstituting by adding bacteriostatic water slowly down the vial side while swirling gently. Never shaking or injecting directly onto the powder.
Source: realpeptides.co ↗ARA-290 vs VIP: Which Is Better? | Real Peptides ARA-290 targets tissue repair through erythropoietin pathways, while VIP modulates immune response via VPAC receptors. Both offer distinct n…
Source: realpeptides.coOpen reference →Semax Amidate vs Modafinil Mechanism — Real Peptides Semax activates BDNF and modulates monoamines; modafinil blocks DAT reuptake. Both enhance cognition through distinct pathways requiring…
Source: realpeptides.coOpen reference →Sermorelin SubQ vs IM Injection Route Better | Real Peptides Subcutaneous sermorelin delivers 85–90% bioavailability with less tissue trauma than IM. Route choice depends on peptide formula…
Source: realpeptides.coOpen reference →Read sources and limitations before applying a claim.
Here's the honest answer: ARA-290 is not a 'neuroprotective drug' in the way that term is used in clinical development. It's a research tool for isolating the tissue-protective arm of erythropoietin receptor signaling without the confounding variable of increased red blood cell production. If you're designing a study to test whether innate repair pathways can reduce neuroinflammation or improve recovery from ischemic injury, ARA-290 allows you to ask that question cleanly. If you're looking for a compound that prevents neuronal death through direct receptor antagonism or ion channel modulation, this isn't the right peptide. Its effects are indirect, mediated through immune signaling and mitochondrial stabilization. The clinical translation of ARA-290 for neuroprotection has stalled precisely because the mechanism doesn't lend itself to acute intervention. The peptide works best when administered early in the injury cascade. Ideally within hours. And requires sustained dosing to maintain effect. That's a challenging profile for stroke or TBI treatment, where intervention windows are narrow and patient heterogeneity is high. Where ARA-290 shines is in research models where you need to understand how tissue-protective signaling modulates secondary injury processes: microglial activation, astrocyte reactivity, blood-brain barrier integrity, and long-term synaptic remodeling. Our experience working with labs across neuroprotection, cardioprotection, and wound-healing models consistently shows this: researchers who treat ARA-290 as a mechanistic probe get reproducible, interpretable results. Researchers who treat it as a therapeutic candidate for clinical translation encounter the same dosing, timing, and CNS penetration constraints that have limited erythropoietin's clinical utility in neurology. Know which question you're asking before designing the protocol. For labs studying how innate repair pathways respond to neuroinflammation, ARA-290 remains one of the cleanest tools available. You can learn about the potential of other research compounds like Cerebrolysin or Dihexa for complementary approaches to neuroprotection research and see how our commitment to precision synthesis extends across our full peptide collection. The peptide's value isn't in replacing existing neuroprotective strategies. It's in revealing how tissue-protective signaling modulates inflammation-driven injury. That's the research question ARA-290 answers better than any alternative compound currently available.
Real Peptides maintains a catalog of over 60 research-grade peptides, spanning growth hormone secretagogues (Ipamorelin, CJC-1295 No DAC), tissue repair compounds (BPC-157, TB-500), metabolic research peptides (Tirzepatide, Retatrutide), nootropic peptides (Semax, Selank), and rare research compounds like FOXO4-DRI for senolytic studies. Every peptide is synthesized specifically for advanced biological research, with formulations optimized for reconstitution stability and subcutaneous administration protocols. The catalog reflects deep peptide expertise. Products like Epithalon and Pinealon represent niche research areas where few suppliers maintain inventory at research-grade purity. PureRawz offers approximately 30–40 peptide products alongside a broader catalog of SARMs, nootropics, and research chemicals. The peptide selection covers common research categories. GLP-1 agonists, growth hormone secretagogues, and basic repair peptides. But lacks the depth in emerging research areas like dual incretin agonists (Survodutide, Mazdutide) or neuroprotective compounds (P21, Cerebrolysin). For laboratories running protocols in cutting-edge metabolic research or longevity studies, the real peptides vs purerawz catalog comparison reveals a meaningful specialization gap. Real Peptides offers advanced stacks like the Wolverine Peptide Stack combining BPC-157, TB-500, and Ipamorelin for multi-pathway research applications. Products designed with research protocol requirements in mind, not generic bundling. Real Peptides also provides Bacteriostatic Water USP-grade for reconstitution, formulated with 0.9% benzyl alcohol to maintain sterility over 28-day multi-dose protocols. A detail that matters when working with peptides sensitive to microbial contamination like KPV or LL-37. PureRawz sells bacteriostatic water as well, but the formulation details and USP certification status are less clearly documented. For researchers prioritizing aseptic technique and contamination prevention, these seemingly minor differences in ancillary products compound over long-term studies.
These excerpts are educational, not personalised medical instructions.
Here's the honest answer: the '2mg daily' TB-4 protocols circulating in online research forums are based on misinterpretation of veterinary wound healing studies that used continuous-infusion pumps, not subcutaneous bolus injections. Those studies maintained constant tissue concentrations through pump delivery. An entirely different pharmacokinetic profile than twice-weekly subcutaneous administration. Applying daily dosing schedules to bolus injection protocols doesn't replicate the original study conditions and significantly increases cost without improving outcomes. The evidence is clear: TB-4's 10-hour half-life makes daily dosing unnecessary for tissue repair applications. Twice-weekly administration during loading phases achieves near-continuous actin saturation because the tissue concentration curve overlaps between doses when administered 3–4 days apart. Daily dosing would require 7× the peptide volume to achieve the same cumulative tissue exposure as a properly structured twice-weekly protocol. The kinetics don't support it. Another persistent claim: 'front-loading' with 20mg single doses accelerates repair. Research using radiolabelled TB-4 shows that doses above 10mg don't proportionally increase tissue uptake because binding sites saturate and excess peptide clears renally within 18 hours. A 20mg dose delivers marginally more tissue exposure than a 10mg dose but costs twice as much and increases injection site inflammation risk. The saturation curve is the constr…
Source: realpeptides.co ↗Peptides are photosensitive. Ultraviolet and visible light both catalyse oxidative degradation of aromatic amino acids, particularly tryptophan, tyrosine, and phenylalanine residues. Adamax contains multiple aromatic residues in its sequence, making light protection a non-negotiable component of proper Adamax storage. Amber glass vials are standard in pharmaceutical peptide packaging specifically because amber glass blocks wavelengths below 450 nm, which includes the UV-A and UV-B spectrum responsible for most photodegradation. If your reconstituted Adamax is in a clear glass vial, store it inside a secondary light-blocking container. A foil-wrapped vial, an opaque plastic box, or even a small cardboard box inside the refrigerator. Direct exposure to fluorescent laboratory lighting for as little as 8 hours can reduce peptide potency by 5–15%, and the degradation is cumulative. This is one of the hidden variables that explains why two researchers following identical protocols sometimes report different results: one stored the vial in a clear compartment under direct light, the other stored it in a drawer. Container material matters beyond light blocking. Peptides are amphipathic molecules. They have both hydrophobic and hydrophilic regions. Which means they adsorb to hydrophobic surfaces like polypropylene and polystyrene plastics. Glass is inert and non-adsorptive, which is why pharmaceutical-grade peptide storage universally uses borosilicate glass vials, not plastic. If yo…
Source: realpeptides.co ↗